**Core Concept**
The RET proto-oncogene is a tumor suppressor gene involved in the regulation of cell growth and division. It encodes a receptor tyrosine kinase that plays a crucial role in the development and function of the nervous system, kidneys, and other organs.

**Why the Correct Answer is Right**
The RET proto-oncogene is activated by its ligand, glial cell line-derived neurotrophic factor (GDNF), which binds to the extracellular domain of the RET receptor. This binding triggers a cascade of intracellular signaling events, including the activation of downstream kinases and the phosphorylation of various proteins. The RET pathway is essential for the development and maintenance of the enteric nervous system, kidneys, and other organs. Mutations in the RET gene can lead to the development of multiple endocrine neoplasia type 2 (MEN2), a rare genetic disorder characterized by the occurrence of medullary thyroid carcinoma, pheochromocytoma, and hyperparathyroidism.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because the RET proto-oncogene is not directly associated with the development of breast cancer. While some cancers may exhibit aberrant RET signaling, this is not a characteristic of breast cancer specifically.
**Option B:** This option is incorrect because the RET proto-oncogene is not a transcription factor. It encodes a receptor tyrosine kinase that regulates cell growth and division through signaling pathways.
**Option C:** This option is incorrect because the RET proto-oncogene is not directly involved in the regulation of blood pressure. While some cancers may exhibit aberrant RET signaling, this is not a characteristic of hypertension specifically.

**Clinical Pearl / High-Yield Fact**
The RET proto-oncogene is a key player in the development and function of the enteric nervous system, and mutations in this gene can lead to the development of Hirschsprung's disease, a congenital disorder characterized by the absence of ganglion cells in the distal colon.

**Correct Answer: D. Multiple Endocrine Neoplasia Type 2 (MEN2)